SAN DIEGO, May 19 /PRNewswire/ -- Sangart, Inc., a privately held
biopharmaceutical company focused on the research, development and
commercialization of therapeutic oxygen transport agents today announced
that it has completed enrollment in the second Phase III trial of its lead
Sangart expects the top line results from this trial to be available in
the second half of 2008.
The 370-patient randomized, double-blind, controlled Phase III study
was conducted at 18 clinical sites in six European countries. Together with
another Phase III study completed in March, the trials were designed to
evaluate the safety and efficacy of Hemospan for preventing and treating
hemodynamic instability, particularly hypotension, or low blood pressure,
during primary hip replacement surgery.
Dr. Robert Winslow, Chairman, President and CEO of Sangart, commented,
"The completed enrollment in this second Phase III trial represents another
significant milestone for Sangart as we advance the development of
No similar oxygen transport agents are currently on the market in
Europe or the United States. Extensive preclinical efficacy studies and
earlier clinical trials indicate that Hemospan's novel oxygen delivery
mechanism has the potential to enhance oxygenation of ischemic tissues and
may provide a safe and effective alternative to blood transfusion,
especially when blood is not immediately available.
Sangart is a privately held San Diego-based biopharmaceutical company
focused on the research, development and commercialization of medical
products designed for use as therapeutic oxygen transport agents and
potential alternatives to blood transfusions.
Dr. Robert Winslow, a world-renowned authority in the field of oxygen
transport, founded Sangart in 1998. In the two decades prior to founding
Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of
oxygen transport by cell-free hemoglobin solutions, funded by competitive
grants from the National Institutes of Health and the Department of
Defense. The counterintuitive discoveries by Dr. Winslow's group on the
effective action of oxygen transport agents have been patented and
published in numerous scientific articles. From this experience, Sangart's
lead product, Hemospan, was designed using unique polyethylene glycol
conjugation to create a hemoglobin-based product that is intended to serve
as an alternative to transfusion of donor blood.
The key breakthroughs in the development of Hemospan were the
understanding of the mechanisms of vasoconstriction and the development of
simplified production methods that are designed to make the final product
commercially viable. These breakthroughs laid the groundwork for Sangart's
business concept of developing cost-effective oxygen transport agents that
can be used in lieu of transfused red blood cells during episodes of
temporary blood loss, such as surgery or trauma.
To learn more about Sangart, please visit the company's website at
Richard Lewis Communications, Inc.
SOURCE Sangart, Inc.